Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$199.88M+48889.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vikram Karnani
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 423
- Beta
- 0.72
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.93
Financials
Revenue
$199.88M+48889.7%Net Income
$-15.05MEBITDA
$70.75MFree Cash Flow
$70.83MEPS (diluted)
$-0.46Shares Outstanding (diluted)
32.46M+38.4%Operating Expenses
$106.59MCash & Debt
$129.47MReturn of Capital
$0.00Revenue by Segment (annual)
$617.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $780.57M | $62.87M | $1.98 |
| 2024 | $631.45M | $69.19M | $2.14 |
| 2023 | $566.77M | $48.16M | $1.60 |
| 2022 | $463.93M | $-25.00M | $-0.74 |
| 2021 | $276.87M | $71.52M | $2.05 |
| 2020 | $310.02M | $26.75M | $0.78 |
| 2019 | $296.70M | $-22.72M | $-0.24 |
| 2018 | $280.41M | $-39.13M | $-1.19 |
| 2017 | $28.48M | $-74.86M | $-2.47 |
| 2016 | $1.71M | $-94.18M | $-3.88 |
| 2015 | $0.00 | $-27.25M | $-2.01 |
| 2014 | $0.00 | $-17.92M | $-2.40 |
| 2013 | $0.00 | $-16.20M | $-2.17 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.91
- Implied price
- $67.01
- Return from $22.02
- 24.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $33.32 — today's price is already 33.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -2.0% | 6.7% | 10.2% | 13.4% | 16.2% | 18.7% |
| 3.0% | 12.2% | 15.9% | 19.1% | 22.1% | 24.8% |
| 8.0% | 17.6% | 21.5% | 24.9% | 28.0% | 30.9% |
| 13.0% | 23.0% | 27.1% | 30.7% | 34.0% | 36.9% |
| 18.0% | 28.5% | 32.7% | 36.5% | 39.9% | 43.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·20d ago·Positive
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Collegium Announces $50 Million Accelerated Share Repurchase Program STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR a…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.78 per share
Typical surprise +11.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.92 vs $1.72beat
- Thu, May 7$1.76 vs $1.52beat
- Thu, Feb 26$2.04 vs $2.14miss
- Thu, Nov 6$2.25 vs $1.86beat
- Thu, Aug 7$1.68 vs $1.62beat
- Thu, May 8$1.49 vs $1.43beat
Estimates and results for COLL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COLL officers and directors.
- Bought
- —
- Sold
- $15.4m
0 trades
37 trades
- Freund John Gordonsold
- Freund John Gordonsold
- Lurker Nancysold
- Bohlin Garen Gsold
- Dieter Davidsold
- Dieter Davidsold
- Dreyer Scottsold
- Dreyer Scottsold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in COLL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.